Daily Ards Research Analysis
Analyzed 7 papers and selected 3 impactful papers.
Summary
A national prospective platform (APS Consortium) is rapidly generating deeply phenotyped ARDS, pneumonia, and sepsis cohorts to enable biologically informed trials. A meta-analysis found ultra-low tidal volume ventilation lowers driving pressure but does not reduce mortality versus standard low tidal volume in ARDS. A randomized Phase 2b trial of aerosolized surfactant in preterm RDS did not meet its primary endpoint at the pre-specified high dose, though an exploratory low-dose signal emerged.
Research Themes
- Precision phenotyping platforms for critical illness (ARDS, pneumonia, sepsis)
- Ventilation strategies and ECLS interfaces in ARDS
- Noninvasive pulmonary therapeutics in neonatal RDS
Selected Articles
1. The ARDS, Pneumonia, and Sepsis (APS) Consortium: Rationale, Design, and Feasibility of a National Platform for Phenotyping Critical Illness Syndromes.
A multicenter, prospective platform enrolled the first 1,000 critically ill adults in under 13 months with exceptionally high biospecimen capture, enabling biological phenotyping of ARDS, pneumonia, and sepsis. Expert adjudication confirmed syndrome classifications, demonstrating feasibility for a 4,000-patient precision cohort.
Impact: Creates a scalable national infrastructure to biologically subclassify critical illness and accelerate targeted trials. Early feasibility metrics are strong, with wide-ranging biospecimen breadth.
Clinical Implications: Near-term, this platform will enable biomarker-driven enrichment strategies and mechanistic endotypes for ARDS, pneumonia, and sepsis trials, potentially improving trial success and personalization.
Key Findings
- Recruited 1,000 critically ill adults in <13 months, ahead of schedule
- High biospecimen capture: blood 99%, upper respiratory 98%, lower respiratory 37%, urine 80%, GI 65%
- Expert adjudication: 40% ARDS, 52% pneumonia, 89% sepsis; in-hospital 4-week mortality 25%
Methodological Strengths
- Multicenter prospective cohort with rapid enrollment and protocolized biospecimen collection
- Independent expert adjudication of ARDS, pneumonia, and sepsis diagnoses; clinical trial registration
Limitations
- Feasibility report; mechanistic analyses and outcomes by phenotype are pending
- Observational design may be subject to residual confounding despite adjudication
Future Directions: Complete 4,000-patient enrollment; integrate multi-omics and longitudinal recovery metrics to define stable endotypes that predict treatment response.
BACKGROUND: To enhance biological understanding of acute respiratory distress syndrome (ARDS), pneumonia, and sepsis and accelerate therapeutic development in these areas, the National Institutes of Health developed the ARDS, Pneumonia, and Sepsis (APS) Consortium. RESEARCH QUESTION: Is the APS Consortium study rapidly generating data and biospecimens from a large cohort of critically ill adults with ARDS, pneumonia, and sepsis that will facilitate phenotyping of these syndromes? STUDY DESIGN AND METHODS: The APS Consortium Phenotyping Study is a multicenter longitudinal prospective observational cohort study aimed at enrolling 4,000 critically ill adults with ARDS, pneumonia, and/or sepsis over 4 years. Data and biospecimens are collected to characterize many aspects of each participant's chronic health, acute illness, and long-term recovery to facilitate phenotyping-that is, subclassifying ARDS, pneumonia, and sepsis into precise biologically-based subsets with shared pathophysiology. Feasibility of the study was assessed by evaluating the first 1,000 participants in terms of recruitment pace, participant characteristics, biospecimen collection, and proportion with confirmed ARDS, pneumonia, and sepsis based on expert adjudication. RESULTS: The first 1,000 participants were recruited ahead of schedule in less than 13 months. Median age was 64 years, 75% received vasopressors, 50% received invasive mechanical ventilation, and 25% died in the hospital within 4 weeks of enrollment. Biospecimen collection rates were high, with 99% of participants with blood, 98% with upper respiratory swabs, 37% with lower respiratory samples, 80% with urine, and 65% with gastrointestinal samples. Expert adjudication resulted in 40% classified with ARDS, 52% with pneumonia, and 89% with sepsis. INTERPRETATION: The APS Consortium Phenotyping Study is producing a cohort of critically ill adults with ARDS, pneumonia, and sepsis with high severity of disease and a rich set of data and biospecimens. The study will continue to full enrollment of 4,000 participants. REGISTRATION: Clinicaltrials.gov NCT06521502.
2. Safety and Efficacy of a Novel Aerosolized Surfactant (APC-0101) for the Treatment of Respiratory Distress Syndrome in Preterm Infants: A Randomized Phase 2b Study.
In a randomized Phase 2b trial of 261 preterm infants with early RDS, high-dose aerosolized surfactant (APC-0101) did not reduce liquid surfactant instillation compared with control, while an exploratory analysis suggested a reduction with low-dose APC-0101. No differences were observed in other respiratory outcomes.
Impact: Introduces a noninvasive surfactant delivery modality with randomized evidence; results refine dosing hypotheses and de-risk future Phase 3 designs.
Clinical Implications: Current evidence does not support routine use of high-dose aerosolized surfactant via APC-0101 for early RDS; low-dose regimens warrant confirmatory trials before clinical adoption.
Key Findings
- Randomized 261 preterm infants (26–31 weeks) with early RDS to control, low-dose, or high-dose APC-0101
- High-dose APC-0101 did not reduce liquid surfactant instillation vs control (44.2% vs 50.0%; P=0.648, ITT)
- Exploratory analysis showed lower instillation in low-dose APC-0101 (34.9%; P=0.045 vs control); no differences in other respiratory outcomes
Methodological Strengths
- Randomized design with intent-to-treat analysis
- Pre-specified RSS thresholds guiding selection and treatment algorithms; device-drug combination standardized delivery
Limitations
- Primary endpoint negative at pre-specified high dose; low-dose effect is exploratory and hypothesis-generating
- Trial not powered for long-term outcomes; potential dose–response uncertainty
Future Directions: Conduct a confirmatory RCT focused on optimized low-dose regimens, with standardized weaning criteria and longer-term respiratory and neurodevelopmental outcomes.
OBJECTIVE: To evaluate the efficacy of 2 different doses of aerosolized surfactant delivered by a drug/device combination system (APC-0101) in reducing the use of instilled liquid surfactant in preterm infants with respiratory distress syndrome (RDS). STUDY DESIGN: 261 preterm infants at 26-31 weeks' gestation with early RDS who were managed with nasal continuous positive airway pressure (NCPAP) or non-invasive ventilation (NIV) and had not received instilled liquid surfactant were randomized on the first day of life to 1 of 3 groups: control, low dose APC-0101, and high dose APC-0101. Infants in the two APC-0101 groups received up to 4 aerosolized surfactant treatments while on NCPAP/NIV. The primary outcome was the percentage of subjects who were treated with instilled liquid surfactant. Respiratory severity score (RSS) thresholds were pre-specified for subject selection and treatment algorithms. RESULTS: In the intent-to-treat (ITT) sample, the frequency of liquid surfactant instillation in the control group was 50.0% compared with 44.2% in the high dose APC-0101 group (P = 0.648). In exploratory analysis, the incidence of surfactant administration in the low dose APC-0101 group was 34.9% (P = 0.045 vs control). There were no differences between groups in other respiratory outcomes. CONCLUSION: The pre-specified high dose of aerosolized surfactant, delivered with the APC-0101 system, did not reduce the use of instilled liquid surfactant in infants with early RDS. An exploratory analysis of the low dose APC-0101 showed a reduction in instilled liquid surfactant, an observation that may merit evaluation in a subsequent study.
3. Ultra-low versus low tidal volume ventilation in acute respiratory distress syndrome: a systematic review and meta-analysis.
Across six studies (n=1,102), ultra-low tidal volume strategies reduced driving pressure but did not confer a mortality benefit compared with standard low tidal volume ventilation in ARDS. Heterogeneity in ECLS use and illness severity limits conclusions regarding bleeding and length-of-stay.
Impact: Synthesizes the best available comparative evidence on ULTV versus LTV in ARDS, providing a counterbalance to physiologic enthusiasm by showing no mortality benefit to date.
Clinical Implications: Standard low tidal volume ventilation remains preferred for ARDS; ULTV should be reserved for selected cases (often with ECLS) with careful risk–benefit assessment until randomized trials demonstrate outcome benefits.
Key Findings
- Included six comparative studies with 1,102 ARDS patients
- ULTV (<4 mL/kg) associated with lower driving pressure than LTV (4–8 mL/kg)
- No statistically significant mortality benefit of ULTV; LOS and bleeding data confounded by illness severity and ECLS exposure
Methodological Strengths
- Comprehensive multi-database search with explicit ULTV and LTV thresholds
- Meta-analytic synthesis across heterogeneous clinical contexts
Limitations
- Substantial heterogeneity in ARDS severity, ECLS modality, and initiation criteria
- Limited number of studies and potential confounding by indication
Future Directions: Adequately powered randomized trials comparing ULTV (with/without ECLS) to standard LTV, incorporating patient-centered outcomes and bleeding risk mitigation.
BACKGROUND: Low tidal volume (LTV) ventilation improves outcomes in acute respiratory distress syndrome (ARDS), whereas ultra-low tidal volume (ULTV) ventilation may further reduce lung stress but often requires extracorporeal life support (ECLS) to maintain gas exchange. Existing studies differ in ARDS severity, ECLS modality, and indications for ECLS initiation. We aimed to compare ULTV versus LTV ventilation in patients with ARDS. METHODS: A systematic review and meta-analysis of studies published up to April 2024 was conducted using PubMed, EMBASE, Cochrane, and Web of Science databases. Studies comparing ULTV (<4 mL/kg) with LTV (4-8 mL/kg) in ARDS patients were included. RESULTS: Six studies involving 1,102 patients met inclusion criteria. The included studies varied in ARDS severity, ECLS modality, and indications for ECLS initiation. Five studies utilized ULTV with ECLS, and one applied ECLS only when PaO CONCLUSIONS: ULTV is associated with lower driving pressure, but current heterogeneous evidence does not demonstrate a statistically significant mortality benefit. Length-of-stay and bleeding findings should be interpreted cautiously because of differences in illness severity and ECLS exposure. Further adequately powered trials are needed.